Discontinuation because of gastrointestinal symptoms is a real and measurable outcome in the trials
After discontinuation, close monitoring is essential: weight should be checked every 4-8 weeks initially, and for diabetes patients, self-monitoring of blood glucose or continuous glucose monitoring should continue as indicated, with A1C assessment within approximately 3 months of stopping to detect metabolic deterioration early and implement alternative management strategies
Most Common Adverse Reactions (incidence of greater than or equal to 5% and at least twice the rate of placebo): somnolence, fatigue, irritability, insomnia, nightmare, constipation, dry mouth
Compounded semaglutide from licensed compounding pharmacies runs $149$400 per month, though these are not FDA approved
They also stated that in the initial 3 months, weight loss was 6%, and that 25% of it was muscle and bone loss